Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1990-10-12
1994-11-29
Nucker, Christine M.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
536 237, 536 234, 435 691, 435 711, 43525233, 4353201, 4241901, 4242551, C07H 1512, C12P 2106, C12P 2104, C12N 100
Patent
active
053690192
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The present invention relates to a vaccine for immunizing animals against diseases caused by microorganisms producing an osteolytic toxin, a DNA sequence encoding a Pasteurella multocida toxin useful for producing the toxin and as a diagnostic agent, methods of producing and isolating a P. multocida toxin, use of a P. multocida toxin, a monoclonal antibody directed against a P. multocida toxin, a diagnostic agent comprising said monoclonal antibody and the use of said monoclonal antibody for a variety of diagnostic and other purposes.
TECHNICAL BACKGROUND
Atrophic rhinitis is a disease which profoundly affects the bone structure of the porcine snout. The etiological agent which is currently considered to be the cause of growth retarding progressive atrophic rhinitis is toxigenic (toxin-producing) strains of P. multocida which colonize the nasal cavity of pigs (Pedersen and Barfod, 1981, (ref. 1), Rutter and Rojas, 1982, (ref. 2), Elling and Pedersen, 1985, (ref. 3), Pedersen et al. 1988 (ref. 4). It has been that the nasal mucosa are more easily colonized by P. multocida when the resistance to infection is lower such as when the pigs are concomitantly infected with Bordetella bronchiseptica or when the nasal mucosa are exposed to a mild chemical irritant (cf. Pedersen and Elling, 1984, (ref. 5).
The pathological effects of P. multocida infection may be ascribed to a toxin produced by this bacterium. The toxin which has an apparent molecular weight of 143 kd and an actual molecular weight of 146.5 kd induces bone resorption (osteolysis) of the nasal turbinates and other bone structures in the nasal cavity by stimulating osteoclast activity in porcine turbinate bones, and causes impaired osteoblastic bone formation.
The disease is of major economic importance to pig breeders all over the world, since apart from the pathological effects on the nasal (and occasionally facial) bones noted above, it causes a slower growth rate of the infected pigs and consequently higher production costs. Attempts have therefore been made to reduce the occurrence and the significance of P. multocida infection, for instance by the establishment of SPF (specific pathogen free) pigs via cesarean section, or by antibiotic treatment of infected animals or prophylactic vaccination.
Known vaccines for the immunization of animals, principally pigs, against diseases ascribable to P. multocida infection, especially atrophic rhinitis, comprise killed P. multocida cells optionally combined with killed Bordetella bronchiseptica cells (cf. EP 85 469) and/or an inactivated (usually by heat treatment or addition of formaldehyde) toxin-containing extract of toxigenic P. multocida. Vaccines of the latter type are commercially available from Northern Drugs & Chemicals Ltd., Copenhagen, Denmark, under the trademark Atrinord.RTM., as well as from Intervet International BV, Boxmoor, Holland, under the trademark Nobi-vacART.RTM..
The present inventors contemplate that an improved immunogenic effect relative to the known vaccine preparations may be obtained by using a purified and suitably modified toxin preparation for vaccination purposes either to replace the conventional vaccines or as a constituent thereof.
The purification of P. multocida toxin has previously been described. Thus, Foged et al., 1987, (ref. 6) disclose the purification of the toxin by chromatography and polyacrylamide gel electrophoresis. The purified toxin is used solely for studying its toxic and pathological effects. Kamp et al., 1987, (ref. 7) also disclose the purification of the P. multocida toxin for the purpose of clinical studies. They suggest that the purified toxin may be used as an antigen to raise specific antibodies useful for serological tests. Nakai et al., 1984, (ref. 8) disclose a method of purifying the P. multocida toxin by chromatography and polyacrylamide gel electrophoresis. They further disclose the production of polyclonal antibodies directed against the purified toxin which they use to analyse the purity of the purified toxin. It is
REFERENCES:
patent: 4677070 (1987-06-01), Larrick et al.
Young et al PNAS 80:1194-1198 1983 Efficient Isolation of Genes Using Antibody Probes.
Foged et al Femus Microb Letter 43:45-51 1987 Characterization & Biological Effects of the Past, Mult Toxin.
Itakura et al.G350102 Science 209:1401-1405 1980.
Maniates et al Molecular Cloning A Laboratory Manual 1982.
Nakai et al Inf & Immun. 46:429-434 1984.
Nakai et al Research in Vet Science 42:232-237, 1987.
Chanter et al Journ of Microbiol. 132:1089-1097 1986 Partial Purification of an Osteolytic Toxic from P. Multocida.
Chemical Abstracts, vol. 107, (1987), Abstract No. 107:110786w, FEMS Microbiol. Lett. 1987, 43(a), 45-51 (Eng.).
Chanter et al. J. Gen. Microbiol., "Partial Purification of an Osteolytic Toxin from Pasteurella multocida", 132: 1089-97 (1986).
Kim et al. Dialog, file Biosis, Dialog Accession No. 0017115392 (Biosis No. 83054453) Res Rep Rural Dev Adm (Suweon) 28 (Livest. and Vet), 1986, 77-93 (Kim J. Y.) "Studies on immunogenecity of Pasteurella . . . ".
Nakai, et al. Reconstruction of Pasteurella multocida dermonecrotic toxin from three polypeptides, FEMS Microb. Lett., 44: 259-265 (1987).
Dialog, file Medline, Dialog Accession No. 04970881 (NLM Accession No. 83203881) Avian Dis, Jan.-Mar. 1983, 27 (1) pp. 283-291, (Kodama H.) "Soluble fractions of Pasteurella multocida: . . . ".
Dialog, file Medline, Dialog Accession No. 05389686 (NLM Accession No. 85005686) Infect. Immun. Oct. 1984, 46(1) pp. 48-54, (Lugtenberg B.) "Atrophic rhinitis in swine: correlation of . . . ".
Pedersen et al. "The aetiological significance of Bordetella bronchiseptica and P. multocida in atrophic rhinitis of swine", Nord. Vet. Med. 33, pp. 513-522, (1981).
Rutter et al. "Atrophic rhinitis in piglets: Differences in the pathogenicity of Pasteurella multocida in combined infections . . . ", Vet. Rec. 110: pp. 531-535, (1982).
Elling et al. "The pathogenesis of persistent turbinate atrophy induced by toxigenic Pasteurella multocida in pigs", Vet. Pathol. 22: pp. 469-474, (1985).
Pedersen, et al. "Atrophic rhinitis in pigs: Proposal for a revised definition", Vet. Rec. 22: pp. 190-191, (1988).
Pedersen et al. "The pathogenesis of atrophic rhinitis in pigs induced by toxigenic Pasteurella multocida", J. Comp. Pathol. 94: pp. 203-214, (1984).
Foged et al. "Characterization and biological effect of the P. multocida toxin", FEMS Microbiol. Lett. 43: pp. 45-51, (1987).
Kamp et al. "Purification of a heat labile dermonecrotic toxin from culture fluid of Pasteurella multocida" Vet. Microbiol. 13: pp. 235-248, (1987).
Nakai et al. "Purification of dermonecrotic toxin from a sonic extract of Pasteurella multocida SP-72 serotype D", Infect. Immun., 46: 429-434, (1984).
Trummel et al. "Stimulaton of bone resorption by a factor from Actinomyces viscosus", J. Perdont, Res. 14: pp. 263-264, (1979).
Foged Niels T.
Petersen Svend
Intervet International B.V.
Nucker Christine M.
Sidberry H. F.
LandOfFree
Pasteurella vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pasteurella vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pasteurella vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-73559